LXCHEM Q1 FY27 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹968.3 Cr
verified against source
Revenue YoY
40%
reported change
EBITDA
₹114.3 Cr
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Laxmi Organic Industries delivered a strong Q1 FY27 with revenue of ₹968.3 crore, up 40% YoY driven by ~10% volume growth and favorable product mix/pricing. EBITDA surged 272% YoY to ₹114.3 crore with ~11.8% margin, aided by supply chain agility and procurement efficiencies despite elevated freight and energy costs. The Essential segment (74.9% of revenue) grew 50% YoY with 11-12% EBITDA margins, while Specialty (25.1%) posted 17% YoY growth on positive momentum. The H project remains on track with mechanical completion expected early Q3 FY27, followed by customer qualification and Q4 ramp-up, with full FY28 revenue contribution anticipated. The capex cycle is nearing completion with term debt peaking at ~₹610 crore. Key risks include ongoing geopolitical disruptions (West Asia 2.0, China typhoon), raw material price volatility, and margin sustainability given the cyclical nature of the Essential business.
Colored figures show movement against the previous available record.
Guidance to track
- Mechanical completion and stabilization expected in early Q3 FY27, followed by customer qualification in Q3 and ramp-up in Q4 FY27. Phase 2 capitalization (~85% of phase 2 capex) planned for Q2 FY27.
- Full revenue contribution from H project expected in FY28 with ramp-up in Q4 FY27. The project blends Essential (40%) and Specialty (60%) segments.
- Full year capex estimate for FY27, including H project spending, is expected to be in the range of ₹125-150 crore.
- Post H Phase 2 capitalization, incremental quarterly depreciation of ~₹7.5 crore expected, with debt repayment starting next year over 5 years.
Risks flagged
- Q2 is experiencing a 2.0 version of the West Asia crisis unfolding, creating significant supply chain and logistics disruptions beyond Q1 challenges.
- Large typhoon in South China has created bottlenecks for transportation moving into global direction and into India, affecting supply chain in Q2.
- Management acknowledged that Essential margins can swing significantly (Q3 FY26 was under pressure, Q1 FY27 at 11-12%) and guidance is for mid-single digit over cycle—making quarterly sustainability uncertain.
- Key raw materials like methanol and acetic acid spiked ~200% when base indexed at 100 in March, creating uncertainty for Q2 despite recent moderation in acetic acid.
Key quotes
- Essential business is a business to be viewed over the cycle. So we were at low single-digit EBITDA and we have now seen you know high double-digit EBITDA at least 11 to 12%. So we expect over the cycle the essentials to be somewhere the mid-range single-digit EBITDA would be a fair estimation.
- The H project phase one and phase 2 as you are aware that the phase 1 was already capitalized which was around 15 to 18% of the total capex and 85% of the capex for the phase 2 will be capitalized during the second quarter.
- We believe we still remain the leader in electrochemical fluorination and that is something we will leverage. We have a very robust pipeline for our specialty business new product development pipeline. There is an element of leveraging the electrochemical fluorination as a technology platform for some of those projects and in due course we will certainly make public the partnerships that we are lining up.
Research modules